Letter to the EditorEfficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials
References (9)
- et al.
Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis
J Allergy Clin Immunol
(2013) - et al.
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
Lancet
(2016) - et al.
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)
J Am Acad Dermatol
(2016) - et al.
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
J Allergy Clin Immunol
(2014)
There are more references available in the full text version of this article.
Cited by (0)
This work was supported by the National Natural Science Foundation of China (grant nos. 81371735, 81573045, 81573038, and 81600201), the Natural Science Foundation of Jiangsu province (grant no. BK20151066), Open Grant of the Jiangsu provincial Key Laboratory of Molecular Biology for Skin Diseases and STIs (grant no. 2015KF14), and the Milstein Medical Asian American Partnership Foundation.
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to this work.
© 2017 American Academy of Allergy, Asthma & Immunology